•
Dec 30, 2024

Prelude Therapeutics Q4 2024 Earnings Report

Expected Revenue:$0
Expected EPS:-$0.47
+6.0% YoY
Total Revenue
$4M
0
Gross Profit
$3.51M
Previous year: -$331K
-1160.7%
Cash and Equivalents
$134M
Previous year: $233M
-42.6%
Free Cash Flow
-$20.8M
Previous year: -$24.7M
-15.8%
Total Assets
$176M
Previous year: $278M
-36.8%

Prelude Therapeutics

Prelude Therapeutics